Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced the launch of new injectable and oral testosterone replacement therapies (TRT) for eligible men.
This morning’s news release hailed the news as the largest expansion of the company’s men’s health program since first introducing the category last September, giving eligible men more options to treat low testosterone in partnership with licensed providers through Hims.
An estimated 20 million men in the U.S. are affected by low testosterone, which, when left untreated, can lead to feelings of lower energy, reduced muscle mass, lower sex drive, and erectile dysfunction. For years, stigma kept many men quiet about these symptoms, but new research suggests men are starting to open up.
A new survey commissioned by Hims of 2,000 U.S. men ages 18 and older found that men are speaking more openly about testosterone, and the hormonal shifts that come with age.
When asked about what they actually want, 79% of men surveyed say more energy is a higher priority than more muscle, so they can show up more fully at work, in their hobbies and with the people who matter most.
Despite this progress, awareness of treatment hasn’t caught up: the same study shows fewer than half of men surveyed (45%) say they're familiar with specific low T treatments.
HIMS shares edged higher 27 cents to $29.48.
